T. Rowe Price Investment Management’s Pacific Biosciences PACB Stock Holding History

T. Rowe Price Investment Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-217	Closed	-$1K	–	853
2025 Q4	$1K	Hold	217	–	–	﹤0.01%	891
2025 Q3	$1K	Sell	217 -7,082	-97%	-$9.59K	﹤0.01%	875
2025 Q2	$10K	Sell	7,299 -4,881,313	-100%	-$5.64M	﹤0.01%	676
2025 Q1	$5.77M	Sell	4,888,612 -8,232	-0.2%	-$12.6K	﹤0.01%	583
2024 Q4	$8.96M	Buy	+4,896,844	New	+$9.56M	0.01%	558
2024 Q2	–	Sell	-8,397,820	Closed	-$31.5M	–	648
2024 Q1	$31.5M	Buy	8,397,820 +644,039	+8%	+$3.77M	0.02%	457
2023 Q4	$76.1M	Buy	7,753,781 +338,257	+5%	+$2.77M	0.05%	320
2023 Q3	$61.9M	Buy	7,415,524 +1,243,925	+20%	+$14.2M	0.04%	335
2023 Q2	$82.1M	Buy	6,171,599 +751,036	+14%	+$9.13M	0.06%	293
2023 Q1	$62.8M	Sell	5,420,563 -649,976	-11%	-$6.46M	0.05%	334
2022 Q4	$49.7M	Sell	6,070,539 -1,502,019	-20%	-$12.9M	0.04%	356
2022 Q3	$44M	Buy	+7,572,558	New	+$43.4M	0.04%	362

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Investment Management's PACB Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 217 shares — an estimated $1K sold.

T. Rowe Price Investment Management first reported a position in PACB in Q3 2022 and held it in 12 quarters. The position peaked at $82.1M in Q2 2023. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

T. Rowe Price Investment Management reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
T. Rowe Price Investment Management sold 217 Pacific Biosciences shares in Q1 2026, an estimated $1K.
T. Rowe Price Investment Management first reported a position in Pacific Biosciences in Q3 2022 and held it in 12 quarters.
T. Rowe Price Investment Management's Pacific Biosciences position peaked at $82.1M in Q2 2023.
231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.